Nina Herne
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 (0) 70-7147457
Email: nina.herne@lidds.se
Jenni Björnulfson
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 (0) 70-8553805
Email: jenni.bjornulfson@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Financial Calendar
Subscribe for news
Press releases
- 2021-11-22
LIDDS Interim report January – September 2021 - 2021-11-17 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
- 2021-11-15 LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
- 2021-10-04 NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr- 2021-11-17 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
- 2021-11-15 LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
- 2021-09-28 LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
- 2021-07-06 LIDDS – subscription of warrants
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
